Edition:
United States

DBV Technologies SA (DBV.PA)

DBV.PA on Paris Stock Exchange

36.42EUR
15 Dec 2017
Change (% chg)

€0.01 (+0.03%)
Prev Close
€36.42
Open
€36.31
Day's High
€36.66
Day's Low
€35.77
Volume
57,812
Avg. Vol
118,831
52-wk High
€86.64
52-wk Low
€34.89

Chart for

About

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to... (more)

Overall

Beta: 0.35
Market Cap(Mil.): €909.87
Shares Outstanding(Mil.): 24.98
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 35.70
ROE: -- 16.55 15.40

BRIEF-DBV Technologies ‍announces positive data from Phase IIb trial and long-term study of Viaskin Peanut​

* ‍ANNOUNCES PUBLICATION OF POSITIVE DATA FROM PHASE IIB TRIAL AND LONG-TERM STUDY OF VIASKIN PEANUT​

Nov 14 2017

BRIEF-DBV Technologies reports at Sept. 30 cash position of 170.5 million euros

* CASH POSITION AT SEPT. 30, 2017 EUR 170.5 MILLION VERSUS EUR 256.5 MILLION AT DEC. 31, 2016 ‍​ Source text: http://bit.ly/2htbI61 Further company coverage: (Gdynia Newsroom)

Oct 31 2017

BRIEF-DBV Technologies ‍cash position of 170.5 million euros as of September 30​

* ‍CASH AND CASH EQUIVALENTS AS OF SEPTEMBER 30, 2017, WERE EUR 170.5 MILLION, COMPARED TO EUR 256.5 MILLION AS OF DECEMBER 31, 2016 ​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Oct 31 2017

BRIEF-DBV Technologies peanut allergy treatment fails to meet main goal in late-stage study

* DBV Technologies announces topline results of phase III clinical trial in peanut-allergic patients four to 11 years of age‍​

Oct 20 2017

DBV Technologies peanut allergy drug fails key study

DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study, sending its U.S.-listed shares sharply down.

Oct 20 2017

UPDATE 1-DBV Technologies peanut allergy drug fails key study

Oct 20 DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study, sending its U.S.-listed shares sharply down.

Oct 20 2017

DBV Technologies peanut allergy drug fails key study

Oct 20 Drug developer DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study.

Oct 20 2017

BRIEF-DBV Technologies completes blinded period in REALISE study of Viaskin Peanut

* REG-DBV TECHNOLOGIES ANNOUNCES COMPLETION OF BLINDED PERIOD IN REALISE STUDY OF VIASKIN PEANUT

Oct 12 2017

BRIEF-DBV Technologies completes enrollment in Phase III extension study of Viaskin Peanut

* REG-DBV TECHNOLOGIES ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE III EXTENSION STUDY OF VIASKIN PEANUT

Aug 29 2017

BRIEF-DBV Technologies initiates phase III study of Viaskin peanut

* REG-DBV TECHNOLOGIES INITIATES PHASE III STUDY OF VIASKIN PEANUT IN PEANUT-ALLERGIC PATIENTS ONE TO THREE YEARS OF AGE Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Aug 02 2017

Earnings vs. Estimates